HC Wainwright restated their buy rating on shares of CytoDyn (OTCMKTS:CYDY) in a research report sent to investors on Wednesday. HC Wainwright currently has a $2.00 price objective on the biotechnology company’s stock.
“We note that leronlimab is a humanized IgG4 monoclonal antibody that blocks CCR5, which functions in both the progression of cancer metastasis and HIV. Our current valuation of leronlimab does not include its application in cancers. Therefore, positive data in cancer indications could drive additional upside to our price target. In the wake of this update, we reiterate our Buy rating and $1.50 price target. Cytodyn is scheduled to host an investment community conference call on the coming Monday to provide a business update. All combo therapy patients to switch to 700 mg dose. The FDA has recognized that the higher dosage of 700 mg in the monotherapy trial had a much higher response rate than the 350 mg dose used in the combination therapy trial, and has agreed to accept safety data from 100 patients in the monotherapy trial with the 700 mg dose.”,” the firm’s analyst commented.
CYDY has been the subject of several other reports. Zacks Investment Research raised shares of CytoDyn from a sell rating to a hold rating in a research report on Wednesday, November 21st. ValuEngine upgraded shares of CytoDyn from a hold rating to a buy rating in a report on Thursday, November 1st.
Shares of OTCMKTS CYDY opened at $0.51 on Wednesday. CytoDyn has a twelve month low of $0.06 and a twelve month high of $0.79.
CytoDyn Company Profile
CytoDyn Inc, a clinical-stage biotechnology company, focuses on the clinical development and commercialization of humanized monoclonal antibodies for the treatment and prevention of human immunodeficiency virus (HIV) infection. Its lead product is PRO 140, a therapeutic anti-viral agent, which is in Phase IIb treatment substitution trial, Phase IIb extension study, Phase IIb/III pivotal trial, and Phase IIb/III investigative trial for HIV; and Phase II trial for graft-versus-host disease.
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.